Croda International/£CRDA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Croda International
Founded in 1925, Croda International Plc is a UK-based speciality chemicals company recognized globally for its innovative approach to delivering specialized chemical solutions across a broad range of industries including consumer care and life sciences. Operating within the basic materials sector, Croda develops, manufactures, and markets a wide array of specialty chemicals used in everything from cosmetics and pharmaceuticals to lubricants and plastics. Over the decades, Croda has committed to sustainability and innovation, driving its growth and solidifying its position as in the industry.
- Ticker
- £CRDA
- Sector
- Materials
- Primary listing
- LSE
- Employees
- 5,954
- Headquarters
- Goole, United Kingdom
- Website
- www.croda.com
CRDA Metrics
BasicAdvanced
£5.1B
63.75
£0.57
0.92
£1.11
3.06%
Price and volume
Market cap
£5.1B
Beta
0.92
52-week high
£36.59
52-week low
£24.88
Average daily volume
436K
Dividend rate
£1.11
Financial strength
Current ratio
2.569
Quick ratio
1.563
Long term debt to equity
0.326
Total debt to equity
0.358
Dividend payout ratio (TTM)
194.72%
Interest coverage (TTM)
4.49%
Profitability
EBITDA (TTM)
244.8
Gross margin (TTM)
43.69%
Net profit margin (TTM)
4.61%
Operating margin (TTM)
7.28%
Effective tax rate (TTM)
27.90%
Revenue per employee (TTM)
£290,000
Management effectiveness
Return on assets (TTM)
2.24%
Return on equity (TTM)
3.68%
Valuation
Price to earnings (TTM)
63.752
Price to revenue (TTM)
2.932
Price to book
2.33
Price to tangible book (TTM)
5.5
Price to free cash flow (TTM)
27.712
Free cash flow yield (TTM)
3.61%
Free cash flow per share (TTM)
1.31
Dividend yield (TTM)
3.06%
Growth
Revenue change (TTM)
3.36%
Earnings per share change (TTM)
-43.14%
3-year revenue growth (CAGR)
-2.20%
10-year revenue growth (CAGR)
4.35%
3-year earnings per share growth (CAGR)
-25.70%
10-year earnings per share growth (CAGR)
-8.93%
3-year dividend per share growth (CAGR)
0.92%
10-year dividend per share growth (CAGR)
4.16%
What the Analysts think about CRDA
Analyst ratings (Buy, Hold, Sell) for Croda International stock.
Analyst projections of the future price of Croda International stock.
Bulls say / Bears say
Consumer Care is driving a recovery: first-half sales rose 8%, with group adjusted operating profit up 6.7% and adjusted operating margin improving to 17.7%. (London Stock Exchange RNS)
Croda’s cost programme is already contributing, delivering £18m of efficiency gains in the first half. Management says it remains on track for £100m of efficiency benefits by 2028, which could support further margin growth. (LSE)
Innovation in premium beauty is gaining traction: Beauty Actives sales grew 19% in the first half, and Croda has launched a new patented peptide-delivery ingredient. That gives the company a route to grow through differentiated products rather than relying only on higher volumes. (Personal Care Insights, Croda)
The recovery is uneven across divisions: first-half Life Sciences sales were flat, Crop Protection fell 2%, and Pharma Solutions dropped 17%. This leaves growth reliant on Consumer Care while parts of the portfolio remain under pressure. (London Stock Exchange RNS)
Input-cost inflation linked to the Iran conflict has forced Croda to raise prices in parts of Asia and Europe. If customers resist those increases or costs rise again, margins could be squeezed. (Reuters)
Reported profit still includes material restructuring and other adjustment charges: first-half IFRS operating profit was £115.5m against adjusted profit of £155.8m, including £17.5m of transformation costs and £5.1m of impairments. Persistent costs of this kind could slow the recovery in statutory earnings. (London Stock Exchange RNS)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
CRDA Financial Performance
Revenues and expenses
CRDA Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing CRDA
AllEURUSDGBP
Fund name | Fund size | £CRDA weighting |
|---|---|---|
iShares STOXX Europe 600 Chemicals€EXV7 | €103M | 2.54% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.38% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.38% |
iShares STOXX Europe Mid 200€EXSD | €610M | 0.35% |
iShares Core FTSE 100£ISF | £17B | 0.20% |
Latest price is delayed by 15 minutes. Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by London Stock Exchange, through Infront.